Dacomitinib>98.0%(HPLC)50mg

8-tert-Butyl 2-ethyl 3-oxo-8-azabicyclo[3.2.1]octane-2,8-dicarboxylate, 97%, 1g

2,2-Bis(3-amino-4-hydroxyphenyl)hexafluoropropane>98.0%(T)5g

2-Chloro-5-isopropoxyaniline, 97%, 1g

2-(Chloromethyl)-1-(difluoromethyl)-1h-imidazole hydrochloride, 98%, 250mg

(R)-METHYL 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLATE HCL, 95.0%, 25g

3-BROMO-4-FLUORO-5-NITROBENZOTRIFLUORIDE, 95.0%, 250mg

2-(4-morpholinyl)propanohydrazide, 95.0%, 250mg

3-(FLUOROMETHYL)AZEPAN-3-OL HCL, 95.0%, 1g

Recipiente di reazione a flangia piatta cilindrico, graduato (2) Fondo piatto, DN 100, 105 mm, Altezza, 330 mm, 1 Pezzo

6,7-dimethoxy-3-methyl-1-benzofuran-2-carboxylic acid, 95.0%, 1g

4-(1-Ethyl-1 H -pyrazol-4-yl)-thiazol-2-ylamine, 100mg

(3,5-Dimethyl-pyrazol-1-yl)-acetic acid, 99.0%, 5g